RxDoctor Payments Data

Daniel Molinar, MD

Family Medicine · Coral Springs, FLNPI 1891157236

Payments from drug & device makers

$938in general payments, 2019–2025

Across 26 payments — averaging $36.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pacira Pharmaceuticals Incorporated$485
  • Lilly USA, LLC$107
  • BD$87
  • AstraZeneca$76
  • AbbVie$67
  • GSK$63
  • plus $53 from 3 others

What the payments were for

  • Travel & lodging$24126%
  • Food & beverage$69774%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$938 in reported general payments places this provider in the 60th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$13,011
Medicare patients
62
Services billed
107

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban17$15,803
OzempicSemaglutide15$13,592
FarxigaDapagliflozin Propanediol12$8,181
Atorvastatin Calcium47$615
Rosuvastatin Calcium30$508
Albuterol Sulfate HfaAlbuterol Sulfate14$498
Metformin Hcl32$339
Losartan Potassium22$304
Lisinopril29$287
Pantoprazole Sodium18$276
Fluconazole15$259
Amlodipine Besylate17$248
Omeprazole19$222
Metoprolol Succinate16$221
Tamsulosin Hcl16$196

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$18$13,59215 claims
AstraZenecaFarxiga$76$8,18112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Coral Springs

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →